Skip to main content
Clinical Trials/KCT0003789
KCT0003789
Recruiting
未知

A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory anaplastic large cell lymphoma or classical Hodgkin lymphoma

Samsung Medical Center0 sites150 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Samsung Medical Center
Enrollment
150
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Any patient planning to administer BrentuximabVedotin to treat the target disease.
  • 2\) Any patient administering BrentuximabVedotin to treat the target disease.
  • 3\) Any patient tracing BrentuximabVedotin after treating the target disease.
  • 4\) Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin

Exclusion Criteria

  • If conditions for target diseases are not met.
  • If conditions for target patients are not met.
  • If patients do not give written consent to participate in study.

Outcomes

Primary Outcomes

Not specified

Similar Trials